MARKET WIREYahoo Finance • 74d ago
LENSAR (LNSR) Q2 2026 Earnings Call TranscriptALLY system placements accelerate as recurring revenue hits 83% of total sales.
Why LNSR Stock dropped -2.18% Today — RQD Quant Desk Flash
$5.84 -2.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.81
LENSAR Inc. (LNSR) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $73.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LNSR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, LENSAR Inc. (NASDAQ: LNSR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $5.84 (-2.18% 1D, market cap $73.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LNSR ranks #956 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LNSR compare to QTEX and MBOT in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), LNSR carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 39.4%, and ROIC of -35.0%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, LNSR leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LNSR?
▼
Per LNSR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001320350), LENSAR Inc. generated $51.7M in revenue (+12.4% YoY), -$34.3M in net income, and -$14.9M in free cash flow against $71.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.81 (-0.58%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-15.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LNSR)Realized 20D OHLCV Swing Band: ±7%
Deterministic 5-Pillar Attribution (24/100 Composite)
🔍 WHY LNSR SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (33% of score)
20D Institutional Volume Accumulation (±7% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (25% of score)
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$6.37-8.9% Next Q
32
Q2 (-2Q)Grade E$5.80+4.7% Next Q
29
Q3 (-1Q)Grade E$6.07-3.8% Next Q
27
CurrentGrade E$5.84-10.9% Hist 90D α
24
Trajectory: E (32) → E (24)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LNSR Turnaround Squeeze
While LNSR currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.10) and Max Pain ($6.13) forces dealer call-delta covering toward $13.59.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LNSR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LNSR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LNSR Stock dropped -2.18% Today — RQD Quant Desk Flash
LENSAR Inc. (LNSR) dropped -2.18% to $5.84, trading at 11% of its 52-week range ($4.95 – $12.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($4.95 – $12.94) with RSI-14 at 34.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7% around $5.84 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 39.4% gross margin and $0 annual free cash flow.
Live LNSR Headlines & Catalysts
CATALYSTYahoo Finance • 80d ago
LENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability SurgeLENSAR Inc (LNSR) posts 18% revenue growth and its strongest adjusted EBITDA to date, driven by a 20% jump in recurring revenue and expanding US market share.
CATALYSTYahoo Finance • 80d ago
LENSAR Q2 Earnings Call HighlightsLENSAR (NASDAQ:LNSR) reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarte
MARKET WIREYahoo Finance • 81d ago
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser Installed Base Clim
MARKET WIREYahoo Finance • 88d ago
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026ORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, to
RISK WATCHYahoo Finance • 153d ago
Lensar (LNSR) Q1 2026 Earnings TranscriptNick Curtis, Chief Executive Officer; and Tom Staab, Chief Financial Officer of LENSAR, who will provide an overview of recent developments, our go-forward strategy and financial results. Before we begin, I'd like to rem
MARKET WIREYahoo Finance • 195d ago
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside PotentialThe updated analyst narrative around LENSAR now centers on a $10 price target that sits above a model fair value of $8.50 per share, giving you a clear reference point for how some on the Street are framing potential ups
MARKET WIREYahoo Finance • 211d ago
How The LENSAR (LNSR) Story Is Shifting After The Failed Alcon Deal And Target ResetThe reset in LENSAR’s fair value price target from $12.50 to $8.50 puts the recent update to the story front and center for anyone tracking the stock. Analysts are weighing how this new $8.50 level lines up with at least
MARKET WIREYahoo Finance • 215d ago
LENSAR, Inc. Q4 2025 Earnings Call SummaryMoby summary of LENSAR, Inc.'s Q4 2025 earnings call
MARKET WIREYahoo Finance • 178d ago
LENSAR® Reports First Quarter 2026 Results and Provides Business Update7 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in First Quarter 2026; Backlog of 11 ALLY Systems as of March 31, 2026 First Quarter Recurring Revenue was $12.6 million Total Laser Installed Base Climbs
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LNSR)
- ✓Walkthrough of LNSR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LNSR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.66%🛡️ HOLDING TREND SUPPORT
2026-10-30O $6.00H $6.03L $5.76C $5.84VOL 28.8K
RES: $7.20SUP: $5.77SMA50: $7.10SMA200: $7.45
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LNSR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +12.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LNSR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LNSR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LNSR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LNSR)
Health Care Rank #956 of 1016
⚔️ QTEX vs LNSR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LNSR vs. QTEX, MBOT, DAVI, SKIN)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, LENSAR Inc. (LNSR) ranks #956 by composite RQD confidence (24/100, grade E) and #700 by equity capitalization ($73.3M). Within this direct 5-issuer industry benchmark cohort, LNSR leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. DAVI currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with LNSR at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LNSR
ACTIVE
LENSAR Inc. | E | 24/100 | — | 39.4% | -35.0% | -2.18% | $73.3M | Benchmark Subject |
| QTEX QTREX Quantum Ltd. | E | 31/100 | — | 0.7% | -35.0% | -7.58% | $73.9M | /qtex-vs-lnsr → |
| MBOT Microbot Medical Inc. | D- | 41/100 | — | — | -15.8% | -2.68% | $75.2M | /mbot-vs-lnsr → |
| DAVI Davion Healthcare Plc | D | 47/100 | — | — | — | -37.55% | $67.3M | /davi-vs-lnsr → |
| SKIN SkinHealth Systems Inc. (Class A) | D- | 36/100 | — | 65.3% | -26.9% | -2.07% | $66.0M | /skin-vs-lnsr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001320350In its most recent audited fiscal period (FY2025, filed 2025-12-31), LENSAR Inc. (LNSR) reported GAAP revenue of $51.7M (+12.4% vs. FY2024 revenue of $46.0M , and +44.6% cumulative change since FY2023) , GAAP net income of -$34.3M, operating cash flow of -$14.8M, and free cash flow of -$14.9M (-513.5% YoY). On the balance sheet, LNSR closed FY2025 with $71.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $51.7M | -$34.3M | -$14.8M | -$14.9M | $71.4M | — |
| FY2024 (FY) | 2024-12-31 | $46.0M | -$31.4M | -$2.3M | -$2.4M | $66.3M | — |
| FY2023 (FY) | 2023-12-31 | $35.7M | -$14.4M | -$9.7M | -$9.7M | — | — |
3. LNSR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, LENSAR Inc. (NASDAQ: LNSR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $5.84 (-2.18% 1D, market cap $73.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LNSR ranks #956 in composite RQD confidence.
How does LNSR compare to QTEX and MBOT in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), LNSR carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 39.4%, and ROIC of -35.0%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, LNSR leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LNSR?
Per LNSR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001320350), LENSAR Inc. generated $51.7M in revenue (+12.4% YoY), -$34.3M in net income, and -$14.9M in free cash flow against $71.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LNSR trading relative to its 50-day, 200-day, and 52-week technical levels?
LNSR last traded at $5.84 (-2.18% on volume of 28,839 shares), positioning the stock -17.75% below its 50-day simple moving average ($7.10) and -21.61% below its 200-day simple moving average ($7.45). Across its 52-week range of $4.95 to $12.94, LNSR sits at the 11.1% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.0% ($5.43 to $6.25).
LNSR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LNSR stock moving today?
Why LNSR Stock dropped -2.18% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 24/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
LNSR — LENSAR Inc.: What the Facts Mean to a Prospective Investor
Engine: roarable-bundle-v1
As of: 2026-11-02T15:08:05Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD 5-pillar rating engine, LENSAR Inc. (LNSR) carries a composite score of 24 / 100 (E — Roarable Strong Sell — Forensic Risk / Avoid).\n- Fundamental Cash Engine (2 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of -20.33% and gross margin of 39.4%.\n- Institutional 13F Whale Flow (8 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Medical/Dental Instruments cohort.\n- Insider & Congressional Conviction (3 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (6 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (5 / 20): Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt-to-Equity of 0.50.
Snapshot
Business & Sector Positioning
LENSAR Inc. (LNSR) is a NASDAQ-listed Health Care issuer operating in Medical/Dental Instruments with a market capitalization of $0.1B.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Operating within Medical/Dental Instruments (Health Care), LNSR exhibits an operating margin of -47.6% and net margin of -60.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (39.4%), and valuation discipline (current multiple) relative to free cash flow conversion.
Open Questions for Prospective Investors
- How sustainable is LNSR's current operating margin (-47.6%) and ROIC (-35.0%) over the next four quarters?\n2. Does the current valuation multiple (current EV/EBITDA) adequately discount macro sensitivity (Beta 1.00) in Medical/Dental Instruments?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 0.20)?
LNSR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for LENSAR Inc. (LNSR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 74d ago
LENSAR (LNSR) Q2 2026 Earnings Call Transcript ALLY system placements accelerate as recurring revenue hits 83% of total sales.
🟢 CATALYST Yahoo Finance • 80d ago
LENSAR Inc (LNSR) (Q2 2026) Earnings Call Highlights: Record Revenue and Profitability Surge LENSAR Inc (LNSR) posts 18% revenue growth and its strongest adjusted EBITDA to date, driven by a 20% jump in recurring revenue and expanding US market share.
🟢 CATALYST Yahoo Finance • 80d ago
LENSAR Q2 Earnings Call Highlights LENSAR (NASDAQ:LNSR) reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarte
🟡 MARKET WIRE Yahoo Finance • 81d ago
LENSAR® Reports Second Quarter 2026 Results and Provides Business Update 10 ALLY Robotic Cataract Laser Systems® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Total Laser Installed Base Clim
🟡 MARKET WIRE Yahoo Finance • 88d ago
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026 ORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, to
🔴 RISK WATCH Yahoo Finance • 153d ago
Lensar (LNSR) Q1 2026 Earnings Transcript Nick Curtis, Chief Executive Officer; and Tom Staab, Chief Financial Officer of LENSAR, who will provide an overview of recent developments, our go-forward strategy and financial results. Before we begin, I'd like to rem
🟡 MARKET WIRE Yahoo Finance • 195d ago
How The Failed Alcon Deal Is Reframing The LENSAR (LNSR) Story And $10 Upside Potential The updated analyst narrative around LENSAR now centers on a $10 price target that sits above a model fair value of $8.50 per share, giving you a clear reference point for how some on the Street are framing potential ups
🟡 MARKET WIRE Yahoo Finance • 211d ago
How The LENSAR (LNSR) Story Is Shifting After The Failed Alcon Deal And Target Reset The reset in LENSAR’s fair value price target from $12.50 to $8.50 puts the recent update to the story front and center for anyone tracking the stock. Analysts are weighing how this new $8.50 level lines up with at least
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
LNSR Bull vs. Bear Conversation Board — What's Your Call at $5.84?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LNSR 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $5.14 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is LNSR (E • RQD 24/100) a Buy at $5.84?
Welcome to the LNSR (LENSAR Inc.) Roar Pit. Current RQD Composite is 24/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $4.67 (-20.0%)
Spot @ $5.84 Pump the brakes on LNSR — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on LNSR, but look at what you are paying: current EV/EBITDA multiples with 39.4% gross margins. Unless LENSAR Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $7.18 (+22.9%)
Spot @ $5.84 LNSR cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on LNSR, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $5.84 (52-wk range $4.95 - $12.94), any beat on forward guidance forces shorts and underweight funds to chase.